Innobiochips
Innobiochips
Biomarkers CoViDiag

5 antigens combination to enhance SARS-CoV2 serological test performances

CoViDiag is a High-Resolution COVID-19 serological analysis device. Developed with the cutting-edge multiplex SirYus technology, it simultaneously detects and identifies 5 antibodies produced against the SARS-CoV-2 virus, offering very precise and reliable results, with exhaustive immune profiling.

 

CoViDiag is a High-Resolution COVID-19 serological device. Developed with the cutting-edge multiplex SirYus technology, it simultaneously detects and identifies 5 antibodies produced against the SARS-CoV-2 virus, offering very precise and reliable results, with exhaustive immune profiling.

Perfectly automatable on several mainstream devices, CoViDiag is a very competitive technology, that enables to test and characterize several hundred samples a day.

Key points of CoViDiag

biomarkers1

  • High Performances : 99% specificity and 98,2% sensitivity*
  • High Definition : 5 antigens tested in one test (anti-N, anti S1, anti-S1-RBD, anti-S2, anti-S1-NTD)
  • Flexibility : Various isotypes detection 
  • Simplicity : Same Protocol as an ELISA Test
  • Adaptability : Standard lab equipment : Quick visual interpretation **

*Diagnostic sensitivity on plasma samples collected over 8 days after symptoms onset and infection confirmed by rt-PCR.
**Automated interpretation is available on a specific reader.

References

An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. J Clin Med. 2020 Nov 21;9(11):3752.

Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis. J Clin Med. 2021 Apr 21;10(9):1815.

CoViDiag Product Range

ProductsReferences
96-tests kit SirYus CoViDiag RUO for IgG detection #2001
96-tests kit SirYus CoViDiag RUO for IgM detection #2004

 

To obtain Covidiag kits and assistance, please contact us using the following form:

You can also contact us directly
by phone: +33 (0)3 28 55 51 29
or by email: covidiag@innobiochips.fr